In addition, the mutant cells exhibit a reduced ability to cause disease relapse in TKI-treated recipient mice, indicating that Gdpd3-mediated lysophospholipid metabolism is a major contributor to the maintenance of CML stem cells in vivo. The gene discussed is GDPD3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.